The
Laboratory Centrifuge Market was valued at USD 2.52 Billion in 2023. The Global Laboratory Centrifuge Market size is estimated to grow at a CAGR of 4% over the forecast period.
A laboratory centrifuge is a motor-driven device commonly used in labs to spin liquid samples at high speeds. This equipment relies on the sedimentation principle, where centripetal acceleration helps separate substances based on their density. Heavier particles in the sample move outward, while lighter ones remain closer to the centre, allowing for efficient separation of components like cells, proteins, or nucleic acids. The Laboratory Centrifuge companies contribute to the market with innovative, high-quality centrifuges, driving a dynamic and evolving landscape.
The competitive landscape of laboratory centrifuge manufacturers is dominated by key players like Thermo Fisher Scientific, Inc., Danaher Corporation, and Eppendorf AG, which lead the market with their broad range of high-performance centrifuges and extensive global reach. KUBOTA Corporation, Sigma Laborzentrifugen GmbH, and Andreas Hettich GmbH & Co.KG are known for their innovative centrifuge designs and reliable products tailored to specific scientific and clinical needs. Companies like NuAire, QIAGEN N.V., Sartorius AG, and HERMLE Labortechnik GmbH bring strong expertise in research and development, offering specialised solutions for niche applications. Cardinal Health and Centurion Scientific contribute to the market with cost-effective, practical solutions for medical and research laboratories. Bio-Rad Laboratories, Inc., Agilent Technologies, and Haier Biomedical further enhance competition with a focus on technological advancements and expanding their product portfolios, creating a dynamic and evolving market for laboratory centrifuge solutions. Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific is a trusted leader in centrifugation solutions, offering a wide range of centrifuges and innovative rotors tailored to meet diverse laboratory needs. Their products cater to critical steps in sample separation across various applications such as clinical diagnostics, genomics, cell culture, blood banking, and bioprocessing. The company provides benchtop and floor model centrifuges with a variety of configurations, along with a comprehensive selection of rotors and labware, such as microplates and large-capacity bottles, designed to ensure optimal performance. Thermo Fisher's offerings extend to clinical and bioprocessing centrifuges, providing high-quality solutions for in vitro diagnostics, blood banking, and bioseparations like cell therapies and vaccine production. Their centrifuges are known for reliability, performance, and flexibility, backed by strong service and support. The company also emphasizes innovation in single-use, sterilized systems that enhance efficiency and reduce contamination risks, making it a go-to partner for labs seeking trusted expertise in separation technologies. The Thermo Fisher Scientific, Inc. Laboratory Centrifuge initiatives such as expanding the retail network, introducing regionally relevant products, and implementing culturally sensitive marketing strategies that are based on thorough customer insights.
Danaher Corporation
Danaher Corporation is a global leader in life sciences and diagnostics, committed to driving innovation and improving human health. With a strong portfolio and exposure to attractive end markets, the company is positioned for long-term revenue growth. In 2023, Danaher underwent a transformative year with the successful spin-off of Veralto, allowing the company to focus solely on life sciences and diagnostics. The acquisition of Abcam a provider of proteomic research consumables, further expanded Danaher's presence in drug discovery and disease research. The company operates using the Danaher Business System (DBS), a framework that has been key to improving operational efficiency, driving growth investments, and market penetration. Danaher's commitment to deploying cutting-edge science and technology is reflected in its wide range of products such as analytical ultracentrifuges, benchtop centrifuges, high-speed centrifuges, and ultracentrifuges. With over 63,000 associates worldwide, Danaher remains dedicated to advancing its mission of accelerating the impact of tomorrow's science and technology. The company's continued focus on strategic acquisitions and portfolio transformation aligns with its long-term vision for sustainable growth and innovation.
Recent Development:
• On June 12, 2023, BD (Becton, Dickinson and Company launched the BD FACSDuet Premium System, a new robotic solution designed to automate sample preparation for clinical flow cytometry diagnostics. This system integrates liquid-handling robotics to manage the entire preparation process, including cocktailing, washing, and centrifuging, and then seamlessly transfers samples to the BD FACSLyric Clinical Flow Cytometry System. The automated "walkaway" workflow reduces manual steps, resource use, and user interaction, enhancing standardization and reproducibility in cellular diagnostics. The BD FACSDuet Premium System is now available globally and has received IVD status in the U.S. and Europe. This innovation aims to streamline clinical lab workflows, allowing professionals to focus more on sample analysis and outcomes. Steve Conly, worldwide president of BD Biosciences, highlighted the system's role in advancing automation and improving diagnostic efficiency.
• In July 2024, Hettich Group, a family-owned leader in life science equipment based in Southern Germany, entered into a growth partnership with Bregal Unternehmerkapital (BU). BU acquired a minority stake in Hettich through a capital increase. This partnership aims to support Hettich's expansion, particularly in Asia and the USA, leveraging BU's global network. Hettich specializes in laboratory centrifuges and refrigeration systems for medical and clinical applications and is recognized as the global leader in robotic centrifuges. The collaboration drive further international growth, pending customary regulatory approvals.
• In April 2023, Eppendorf launched the Centrifuge 5427 R, the company's first microcentrifuge featuring hydrocarbon cooling. This innovative model uses R290 (propane), a natural cooling agent with a Global Warming Potential (GWP) close to zero, making it a more sustainable choice compared to conventional refrigerants like R134a, which have a GWP of 1430. The Centrifuge 5427 R is certified with the ACT label, providing third-party verified information on its environmental impact. It offers a compact design and dual-row rotor FA-45-48-11, accommodating up to 48 x 1.5/2 mL tubes, making it ideal for high sample throughput in molecular and cell biology labs.
